Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
Objectives: This study aimed to describe the longitudinal evolution of neutralizing antibody titres (NtAb) in three different cohorts of healthcare workers (HCWs), including vaccinated HCWs with and without a previous SARS-CoV-2 infection and previously infected unvaccinated HCWs. COVID-19 was mild...
Guardado en:
Autores principales: | Ilaria Vicenti, Monica Basso, Francesca Gatti, Renzo Scaggiante, Adele Boccuto, Daniela Zago, Eliana Modolo, Filippo Dragoni, Saverio Giuseppe Parisi, Maurizio Zazzi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/977f1397ef8f44b082acf510e02bdd60 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns
por: Matteo Nioi, et al.
Publicado: (2021) -
Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
por: Rana Shibli, et al.
Publicado: (2021) -
Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
por: Hamad Ali, et al.
Publicado: (2021) -
Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
por: Mohammad Shehab, et al.
Publicado: (2021) -
B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies
por: Federica Pulvirenti, et al.
Publicado: (2021)